Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.